ELI LILLY COO: ZYPREXA SALES DOWN GLOBALLY, WILL HURT 2Q
Eli Lilly & Co. (LLY) Chief Operating Officer John
C. Lechleiter said Thursday that sales of the company's drug Zyprexa are down,
which will have an impact on the company's second quarter. Earlier Thursday, the
pharmaceutical company posted first-quarter results that beat analyst expectations
on strong Cymbalta sales, which doubled in the U.S. and globally this quarter
compared to a year earlier.